March 9, 2022 8:01am

Some sessions, volatility is to be loved, while others to be hated and we are NOT done with both of them

Pre-open indications: 3 SELLs indications, 1 BUY Indication and 1 pimp/pump/promote

RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Only the facts … I ask questions and note the indications of what could happen …

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

 

Dow futures are UP +1.49% (+486 points), S&P futures are UP +1.61% (+67 points) and NASDAQ futures are UP +% (+265 points)

 

Stock futures posted strong gains in Wednesday’s pre-open, the gains are coming amid an easing in commodity prices that have spooked the broader market,

European markets were sharply higher,

Asia Pacific markets were mixed with Hong Kong’s Hang Seng index leading losses among major indexes.

 

Henry’omics:

A quick reminder from others, “Given the ongoing geopolitical uncertainty and push to isolate Russia from the global economy, some strategists suggested investors should brace for more market volatility.” <yahoo finance>

Indexes all closed lower after a day of choppy trading as the Dow gave up a 585-point gain to end the day lower by 184 points, or -0.5%, the S&P 500 slid 30.39 points or 0.7% while the Nasdaq lost 35.41 points or -0.2%.

 

Economic data Docket: homebuying data from the Mortgage Bankers Association as well as the job openings and labor turnover survey, or JOLTS.

 

RegMed Investors’ (RMi) closing bell: “RegMed Investors’ (RMi) closing bell: news, earnings and oversold conditions drive sector’s risk slide” … https://www.regmedinvestors.com/articles/12332

Ebb and flow –

·         March – 4 negative and 2 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 1 holiday, 1 neutral, 13 negative and 6 positive closes

 

Research Notes:

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ... (VYGR) added - 24 total to date

 

Companies in my headlights – It’s your decision; I provide ideas and context:

BUY: a bounce

Beam Therapeutics (BEAM) closed down -$0.34 to $62,47 with a positive +$0.03 or +0.05% pre-open indication,

 

SELL:

Voyager Therapeutics (VYGR) closed up +$1.31 or +33.33% with a negative -$0.30 or -5.73% pre-open indication.

Intellia Therapeutics (NTLA) closed up +$0.79 after Monday’s -$2.18, Friday’s -$5.93, Thursday’s -$13.42 and last Wednesday’s +$4.54 with a negative -$0.27 or -0.42% pre-open indication

Regenxbio (RGNX) closed up +$1.71 or +6.21% to $29.24 with a negative -$0.01 or -0.03% pre-open indication and a “tippy” chart.

 

Pimp/Pump and Promote:

Biostage (OTCQB: BSTG) closed flat (having been up +$0.14) with 1,142 shares traded after Monday’s +$0.29 with 399 shares traded after Friday’s -$0.44 with 1,300 shares traded, Thursday’s +$0.25 with 487 shares traded, Wednesday’s +$0.34 with 649 shares traded, and last Tuesday’s -$0.04 with 4,359 shares traded …

  • WHO is BUYING these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
  • Also, by use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering - they’re NOT going ANYWHERE without a cash inflow.

 

The BOTTOM LINE: the cell and gene therapy sector is in for a correction again after the multiple February agains (negative advance/decline lines – 11 out of 20 sessions).

As I stated yesterday, bounce, baby, bounce.

Earnings’ reporting on the horizon:

·         Athersys (ATHX), Tuesday, 3/15

·         Cellectis SA (CLLS) Thursday, 3/22

Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency and more; it takes courage, resolve and patience to stay the course of asking the questions without response!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider their investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.